Please ensure Javascript is enabled for purposes of website accessibility

Here's Why Esperion Therapeutics Inc. Stock Is Bouncing Back Today

By Cory Renauer - May 4, 2018 at 12:59PM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Bargain hunters willing to accept big risks are pushing shares back up.

What happened

Shares of Esperion Therpeutics Inc. (ESPR 2.86%), a clinical-stage biotech, are bouncing back after a recent market beatdown. A dramatic price reduction is bringing bargain shoppers out of the woodwork. The stock rose as high as 17.1% in early morning trading, but has since settled to a 11.3% gain as of 12:10 p.m. EDT.

So what 

Earlier in the week, Esperion stock tanked after the company revealed 13 patient deaths in a group of 1,487 who received the company's experimental cholesterol-lowering therapy, bempedoic acid, during a late-stage clinical trial. The deaths were considered unrelated to the treatment, but they occurred at a rate three times as high as the group taking statins plus a placebo. Fearing a holdup at the Food and Drug Administration, J.P. Morgan issued a downgrade that pushed the stock down to a level that apparently looks attractive to investors unfazed by the recent safety scare.

Falling stock chart being bent upward by a person in a suit.

Image source: Getty Images.

Bempedoic acid is intended to be a treatment for patients that can't control their LDL cholesterol with cheap generic statins. Adding the drug to maximally tolerated statin therapy led to significant cholesterol reductions, which could make it an important weapon in a war against heart disease that claims the lives of around 600,000 Americans every year. Around 2,400 patients have been treated with bempedoic acid in mid- and late-stage trials and, taken on the whole, the safety data doesn't suggest Esperion's candidate is any more dangerous than the statins it could supplement.

Now what

Esperion is about to give us heaps more bempedoic trial data that could help regulators feel more confident about the drug's risk-to-benefit profile. Later this month, the company will release top-line results from a trial with high-risk patients that can't take statins, and results from a pivotal combination trial with Zetia are due in September.

With a market cap around $1.1 billion at the moment, this cholesterol drug stock could deliver monster gains if its candidate becomes a roaring success. If any severe event imbalances appear in upcoming readouts, though, Esperion could be in serious trouble. Bempedoic acid is the only drug candidate in its pipeline, and earning an approval might be the easy part.

If approved, a recent deal between Express Scripts, Sanofi, and Regeneron could result in Praluent, another next-generation cholesterol-lowering drug, which would compete fiercely with bempedoic acid. Even at today's prices, the risks facing Esperion are so great that I would only recommend it to the most adventurous investors.  

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Esperion Therapeutics Stock Quote
Esperion Therapeutics
ESPR
$6.47 (2.86%) $0.18

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
321%
 
S&P 500 Returns
111%

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 06/25/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.